Literature DB >> 14667110

Service utilisation by children with conduct disorders--findings from the GB National Study.

Panos Vostanis1, Howard Meltzer, Robert Goodman, Tasmin Ford.   

Abstract

BACKGROUND: Children with conduct disorders and their families come into contact with a range of community and specialist agencies.
METHODS: The aim of this study was to establish the lifetime service utilisation rates among children with conduct disorders from the Great Britain National Study (N = 10,438), and to examine the association between comorbid disorders, family and social factors, and service utilisation. The Development and Well-Being Assessment, a service checklist, and a battery of family and social functioning measures were used.
RESULTS: The weighted prevalence of oppositional and conduct disorders was 5.4%. Within this group (N = 403), 241 (59.8%) had conduct disorder only, 79 (19.6%) comorbid emotional, 72 (17.9%) comorbid hyperkinetic, and 11 (2.7%) comorbid emotional and hyperkinetic disorders. These subgroups were compared on service utilisation with children with other psychiatric disorders (N = 351). Children with conduct disorders had significantly higher lifetime rates of utilisation of social and educational services than children with other psychiatric disorders. Contact with primary health, specialist health, and educational services was significantly associated with comorbid physical and psychiatric disorders. In contrast, contact with social services was associated with family discord and social sector tenancy.
CONCLUSIONS: The findings are discussed in the context of organisation and co-ordination of health, other statutory, and non-statutory services, also taking into account previous research on interventions for children with conduct disorders and their families.

Entities:  

Mesh:

Year:  2003        PMID: 14667110     DOI: 10.1007/s00787-003-0330-6

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  6 in total

1.  Treatment for ADHD: is more complex treatment cost-effective for more complex cases?

Authors:  E Michael Foster; Peter S Jensen; Michael Schlander; William E Pelham; Lily Hechtman; L Eugene Arnold; James M Swanson; Timothy Wigal
Journal:  Health Serv Res       Date:  2007-02       Impact factor: 3.402

2.  Cumulative prevalence of psychiatric disorders by young adulthood: a prospective cohort analysis from the Great Smoky Mountains Study.

Authors:  William Copeland; Lilly Shanahan; E Jane Costello; Adrian Angold
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-01-26       Impact factor: 8.829

3.  Service utilization by children with conduct disorders: findings from the 2004 Great Britain child mental health survey.

Authors:  Raghuram Shivram; John Bankart; Howard Meltzer; Tamsin Ford; Panos Vostanis; Robert Goodman
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-04-08       Impact factor: 4.785

4.  Cross-sectional study into the costs and impact on family functioning of 4-year-old children with aggressive behavior.

Authors:  Maartje A Raaijmakers; Jocelyne A Posthumus; Ben A van Hout; Herman van Engeland; Walter Matthys
Journal:  Prev Sci       Date:  2011-06

5.  TIGA-CUB - manualised psychoanalytic child psychotherapy versus treatment as usual for children aged 5-11 years with treatment-resistant conduct disorders and their primary carers: study protocol for a randomised controlled feasibility trial.

Authors:  Elizabeth Edginton; Rebecca Walwyn; Kayleigh Burton; Robert Cicero; Liz Graham; Sadie Reed; Sandy Tubeuf; Maureen Twiddy; Alex Wright-Hughes; Lynda Ellis; Dot Evans; Tom Hughes; Nick Midgley; Paul Wallis; David Cottrell
Journal:  Trials       Date:  2017-09-15       Impact factor: 2.279

6.  Differences in healthcare costs in youths with conduct disorders in rural vs. urban regions: an analysis of German health insurance data.

Authors:  Heike Gerhardt; Monika Heinzel-Gutenbrunner; Christian J Bachmann
Journal:  BMC Health Serv Res       Date:  2018-09-14       Impact factor: 2.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.